Orexo Revisited - Persistence and innovation
2021-04-27 08:10:00
Redeye has revisited Orexo's valuation with an in-depth company study and a re-think of the company’s pipeline potential, especially the digital therapies. We recalculate Orexo’s fair value per share at SEK 80, while we also look at qualitative factors such as culture, innovation and leadership, which while difficult to put into an excel model, are important for sustainable value creation, we argue.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/